Article Text

Download PDFPDF
Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy
  1. A. Kikuchi,
  2. H. Sakamoto and
  3. T. Yamamoto
  1. Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan
  1. Address correspondence and reprint requests to: Hideki Sakamoto, MD, PhD, Associate Professor Obstetrics and Gynecology, Nihon University School of Medicine, 30-1 Oyaguchi, Kamimachi, Itabashi, Tokyo 173-8610, Japan. Email: sakamoto{at}med.nihon-u.ac.jp

Abstract

The safety and efficacy of weekly carboplatin and paclitaxel administration in recurrent ovarian cancers after platinum-containing multidrug chemotherapy were tested. Japanese patients who achieved complete response with surgery and adjuvant platinum-based chemotherapy and who had a recurrence after at least 6 months were included in the case – control study. Twenty-seven cases received the weekly TJ (WTJ) regime (cohort 1: T = 80 mg/m2, J = AUC 2, median course = 13, range = 3–26) and 41 received other regimens [cohort 2: CAP = 37, monthly TJ (MTJ) = 4]. Toxicity profile, response rate, therapeutic index (TI), and survival were analyzed. Neutropenia, thrombocytopenia, and peripheral neuropathy (grades 3 and 4) in cohorts 1 and 2 were 1.7% and 90%, 5.1% and 14.3%, and 0% and 4.8%, respectively. Response rates were 77.8% and. Thus, TI of the two cohorts was 3.9 and 1.9, respectively. The median survival of cohort 1 was 48.3 months (95% CI 11.5–85.0) whereas that of cohort 2 was 17.8 months (95% CI 5.3–30.3, P < 0.005). WTJ has better toxicity profile and TI than monthly platinum-based multidrug regimens for recurrent ovarian cancers in Japanese women. As second-line treatment of ovarian cancer should primarily provide high TI, WTJ regimen appears a better candidate, but its long-term survival benefit should be tested against MTJ.

  • paclitaxel
  • recurrent ovarian cancer
  • weekly carboplatin

Statistics from Altmetric.com

Supplementary materials

Related Data

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.